

CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Cancelled)
2. (Cancelled)
3. (Currently Amended) An isolated polypeptide encoded by ~~the~~ an isolated nucleic acid molecule ~~of claim 1~~ selected from the group consisting of:
 - (a) the DNA sequence of SEQ ID NO:3;
 - (b) an isolated nucleic acid molecule encoding an amino acid sequence comprising the sequence of SEQ ID NO:4;
 - (c) an isolated nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of (a) or (b) under conditions of moderate stringency in 50% formamide and 6XSSC, at 42°C with washing conditions of 60°C, 0.5XSSC, 0.1% SDS;
 - (d) an isolated nucleic acid molecule derived by in vitro mutagenesis from SEQ ID NO:3; or
 - (e) an isolated nucleic acid molecule degenerate from SEQ ID NO:3 as a result of the genetic code.
4. – 8. (Cancelled)
9. (Previously Presented) The polypeptide of claim 3 in a composition comprising a pharmaceutically acceptable carrier selected from the group consisting of water, oils, alcohols, salts, fatty acids, saccharides, polysaccharides and combinations thereof.
10. - 37. (Cancelled)
38. (Original) A vaccine comprising at least a portion of the polypeptide of SEQ ID NO:4.

39. (Currently Amended) A method for treating a patient comprising administering to the patient a therapeutically effective amount of a composition comprising at least an active portion of the polypeptide of ~~SEQ ID NO:2~~ or SEQ ID NO:4.

40. (Original) The method of claim 39 wherein the polypeptide has anti-neoplastic activity.

41. (Original) The method of claim 40 wherein the anti-neoplastic activity is a modulation of chemokine expression.

42. (Withdrawn) The method of claim 40 wherein the anti-neoplastic activity is a modulation of cytokine expression.

43. (Original) The method of claim 39 wherein the therapeutically effective amount of the composition is administered locally to a tumor site, systemically, or parenterally.

44. – 62. (Cancelled)

63. (Previously Presented) The polypeptide of claim 3 wherein the polypeptide has an anti-neoplastic activity.